|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN Estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Testa U, Castelli G and Pelosi E: Lung
cancers: Molecular characterization, clonal heterogeneity and
evolution, and cancer stem cells. Cancers (Basel). 10:2482018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Song J, Sun Y, Cao H, Xi L, Dong C, Yang R
and Shi Y: A novel pyroptosis-related lncRNA signature for
prognostic prediction in patients with lung adenocarcinoma.
Bioengineered. 12:5932–5949. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Al-Dherasi A, Huang QT, Liao Y, Al-Mosaib
S, Hua R, Wang Y, Yu Y, Zhang Y, Zhang X, Huang C, et al: A
seven-gene prognostic signature predicts overall survival of
patients with lung adenocarcinoma (LUAD). Cancer Cell Int.
21:2942021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu J, Hong M, Li Y, Chen D, Wu Y and Hu
Y: Programmed cell death tunes tumor immunity. Front Immunol.
13:8473452022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang S, Wang R, Hu D, Zhang C, Cao P and
Huang J: Machine learning reveals diverse cell death patterns in
lung adenocarcinoma prognosis and therapy. NPJ Precis Oncol.
8:492024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu T, Zhu C, Chen X, Guan G, Zou C, Shen
S, Wu J, Wang Y, Lin Z, Chen L, et al: Ferroptosis, as the most
enriched programmed cell death process in glioma, induces
immunosuppression and immunotherapy resistance. Neuro Oncol.
24:1113–1125. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Singh P and Lim B: Targeting apoptosis in
cancer. Curr Oncol Rep. 24:273–284. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qin Y, Ashrafizadeh M, Mongiardini V,
Grimaldi B, Crea F, Rietdorf K, Győrffy B, Klionsky DJ, Ren J,
Zhang W and Zhang X: Autophagy and cancer drug resistance in
dialogue: Pre-clinical and clinical evidence. Cancer Lett.
570:2163072023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tong X, Tang R, Xiao M, Xu J, Wang W,
Zhang B, Liu J, Yu X and Shi S: Targeting cell death pathways for
cancer therapy: Recent developments in necroptosis, pyroptosis,
ferroptosis, and cuproptosis research. J Hematol Oncol. 15:1742022.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma X, Xiao L, Liu L, Ye L, Su P, Bi E,
Wang Q, Yang M, Qian J and Yi Q: CD36-mediated ferroptosis dampens
intratumoral CD8(+) T cell effector function and impairs their
antitumor ability. Cell Metab. 33:1001–1012.e1005. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang C, Xia J, Liu X, Li Z, Gao T, Zhou T
and Hu K: Identifying prognostic genes related PANoptosis in lung
adenocarcinoma and developing prediction model based on
bioinformatics analysis. Sci Rep. 13:179562023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu K, Zhang Y, Yan Z, Wang Y, Li Y, Qiu Q,
Du Y, Chen Z and Liu X: Identification of disulfidptosis related
subtypes, characterization of tumor microenvironment infiltration,
and development of DRG prognostic prediction model in RCC, in which
MSH3 is a key gene during disulfidptosis. Front Immunol.
14:12052502023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tian Q, Zhou Y, Zhu L, Gao H and Yang J:
Development and validation of a ferroptosis-related gene signature
for overall survival prediction in lung adenocarcinoma. Front Cell
Dev Biol. 9:6842592021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liang JY, Wang DS, Lin HC, Chen XX, Yang
H, Zheng Y and Li YH: A novel ferroptosis-related gene signature
for overall survival prediction in patients with hepatocellular
carcinoma. Int J Biol Sci. 16:2430–2441. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wei J, Zeng Y, Gao X and Liu T: A novel
ferroptosis-related lncRNA signature for prognosis prediction in
gastric cancer. BMC Cancer. 21:12212021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ricci A, Salvucci C, Castelli S, Carraturo
A, de Vitis C and D'Ascanio M: Adenocarcinomas of the lung and
neurotrophin system: A review. Biomedicines. 10:25312022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang SY, Hui LP, Li CY, Gao J, Cui ZS and
Qiu XS: More expression of BDNF associates with lung squamous cell
carcinoma and is critical to the proliferation and invasion of lung
cancer cells. BMC Cancer. 16:1712016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang ZX, Yong Y, Tan WC, Shen L, Ng HS
and Fong KY: Prognostic factors for mortality due to pneumonia
among adults from different age groups in Singapore and mortality
predictions based on PSI and CURB-65. Singapore Med J. 59:190–198.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sinkevicius KW, Kriegel C, Bellaria KJ,
Lee J, Lau AN, Leeman KT, Zhou P, Beede AM, Fillmore CM, Caswell D,
et al: Neurotrophin receptor TrkB promotes lung adenocarcinoma
metastasis. Proc Natl Acad Sci USA. 111:10299–10304. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu Q, Wang Y, Yi G, Yang W, Chen K, Tan X,
Zhang X, Xu Z, Yang Z and Peng Y: BDNF is a prognostic biomarker
involved in immune infiltration of lung adenocarcinoma and is
associated with brain metastasis. Immunology. 168:320–330. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bergman PJ: Cancer immunotherapy. Vet Clin
North Am Small Anim Pract. 54:441–468. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee ES, Son DS, Kim SH, Lee J, Jo J, Han
J, Kim H, Lee HJ, Choi HY, Jung Y, et al: Prediction of
recurrence-free survival in postoperative non-small cell lung
cancer patients by using an integrated model of clinical
information and gene expression. Clin Cancer Res. 14:7397–7404.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou X, Xiao B, Jiang M and Rui J:
Pan-cancer analysis identifies EMC6 as a potential target for lung
adenocarcinoma. iScience. 27:1086482023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rousseaux S, Debernardi A, Jacquiau B,
Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY,
Lantuejoul S, Hainaut P, et al: Ectopic activation of germline and
placental genes identifies aggressive metastasis-prone lung
cancers. Sci Transl Med. 5:186ra66. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hight SK, Mootz A, Kollipara RK, McMillan
E, Yenerall P, Otaki Y, Li LS, Avila K, Peyton M, Rodriguez-Canales
J, et al: An in vivo functional genomics screen of nuclear
receptors and their co-regulators identifies FOXA1 as an essential
gene in lung tumorigenesis. Neoplasia. 22:294–310. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Langfelder P and Horvath S: WGCNA: An R
package for weighted correlation network analysis. BMC
Bioinformatics. 9:5592008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu J, Zhang L, Xia H, Yan Y, Zhu X, Sun F,
Sun L, Li S, Li D, Wang J, et al: Tumor microenvironment remodeling
after neoadjuvant immunotherapy in non-small cell lung cancer
revealed by single-cell RNA sequencing. Genome Med. 15:142023.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Trefny MP, Rothschild SI, Uhlenbrock F,
Rieder D, Kasenda B, Stanczak MA, Berner F, Kashyap AS, Kaiser M,
Herzig P, et al: A variant of a killer cell immunoglobulin-like
receptor is associated with resistance to PD-1 blockade in lung
cancer. Clin Cancer Res. 25:3026–3034. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cho JW, Hong MH, Ha SJ, Kim YJ, Cho BC,
Lee I and Kim HR: Genome-wide identification of differentially
methylated promoters and enhancers associated with response to
anti-PD-1 therapy in non-small cell lung cancer. Exp Mol Med.
52:1550–1563. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim JY, Choi JK and Jung H: Genome-wide
methylation patterns predict clinical benefit of immunotherapy in
lung cancer. Clin Epigenetics. 12:1192020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Malta TM, Sokolov A, Gentles AJ,
Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J,
Omberg L, Gevaert O, et al: Machine learning identifies stemness
features associated with oncogenic dedifferentiation. Cell.
173:338–354.e15. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao Y, Kim S, Lee YI and Lee J: Cellular
stress-modulating drugs can potentially be identified by in silico
screening with connectivity map (CMap). Int J Mol Sci. 20:56012019.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mifflin L, Ofengeim D and Yuan J:
Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic
target. Nat Rev Drug Discov. 19:553–571. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang X, Chen Z, Nie D, Zeng X, Zhong M,
Liu X, Zhong S, Wang L, Liao Z, Chen C, et al: CASP1 is a target
for combination therapy in pancreatic cancer. Eur J Pharmacol.
961:1761752023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hattori T, Fundora KA, Hamamoto K, Opozda
DM, Liang X, Liu X, Zhang J, Uzun Y, Takahashi Y and Wang HG: ER
stress elicits non-canonical CASP8 (caspase 8) activation on
autophagosomal membranes to induce apoptosis. Autophagy.
20:349–364. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hu J, Pan D, Li G, Chen K and Hu X:
Regulation of programmed cell death by Brd4. Cell Death Dis.
13:10592022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hsu SK, Li CY, Lin IL, Syue WJ, Chen YF,
Cheng KC, Teng YN, Lin YH, Yen CH and Chiu CC: Inflammation-related
pyroptosis, a novel programmed cell death pathway, and its
crosstalk with immune therapy in cancer treatment. Theranostics.
11:8813–8835. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hsu SK, Chang WT, Lin IL, Chen YF,
Padalwar NB, Cheng KC, Teng YN, Wang CH and Chiu CC: The role of
necroptosis in ROS-mediated cancer therapies and its promising
applications. Cancers (Basel). 12:21852020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Khan M, Ai M, Du K, Song J, Wang B, Lin J,
Ren A, Chen C, Huang Z, Qiu W, et al: Pyroptosis relates to tumor
microenvironment remodeling and prognosis: A pan-cancer
perspective. Front Immunol. 13:10622252022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pan S, Meng H, Fan T, Hao B, Song C, Li D,
Li N and Geng Q: Comprehensive analysis of programmed cell death
signature in the prognosis, tumor microenvironment and drug
sensitivity in lung adenocarcinoma. Front Genet. 13:9001592022.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang S, Ji J, Wang M, Nie J and Wang S:
Construction of ovarian cancer prognostic model based on the
investigation of ferroptosis-related lncRNA. Biomolecules.
13:3062023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen H, Luo H, Wang J, Li J and Jiang Y:
Identification of a pyroptosis-related prognostic signature in
breast cancer. BMC Cancer. 22:4292022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen Y, Huang W, Ouyang J, Wang J and Xie
Z: Identification of anoikis-related subgroups and prognosis model
in liver hepatocellular carcinoma. Int J Mol Sci. 24:28622023.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Malekan M, Nezamabadi SS, Samami E,
Mohebalizadeh M, Saghazadeh A and Rezaei N: BDNF and its signaling
in cancer. J Cancer Res Clin Oncol. 149:2621–2636. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yeo IJ, Yu JE, Kim SH, Kim DH, Jo M, Son
DJ, Yun J, Han SB and Hong JT: TNF receptor 2 knockout mouse had
reduced lung cancer growth and schizophrenia-like behavior through
a decrease in TrkB-dependent BDNF level. Arch Pharm Res.
47:341–359. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Goto T, Saligan LN, Li X, Xiang L, Kwiat
C, Nguyen C, Crouch A and Von Ah D: Associations of brain-derived
neurotrophic factor rs6265 polymorphism and cognitive function in
breast cancer survivors from a cross-sectional study. Cancer Med.
13:e69752024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu YN, Chen WY, Liu MK, Yeh HL, Chen WH,
Jiang KC, Li HR, Chen ZQ, Wang WH, Abou-Kheir W and Wen YC:
Immunosuppressive role of BDNF in therapy-induced neuroendocrine
prostate cancer. Mol Oncol. 18:1665–1686. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Večurkovská I, Mašlanková J, Tomečková V,
Kaťuchová J, Kisková T, Fröhlichová L, Mareková M and Stupák M:
Stage-dependent levels of brain-derived neurotrophic factor and
matrix metalloproteinase 9 in the prognosis of colorectal cancer.
Biomedicines. 11:18392023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tian J, Cheng H, Wang N and Wang C: SLERT,
as a novel biomarker, orchestrates endometrial cancer metastasis
via regulation of BDNF/TRKB signaling. World J Surg Oncol.
21:272023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Park JE, Kim SE, Keam B, Park HR, Kim S,
Kim M and Heo DS, Doh J, Kim DW and Heo DS: Anti-tumor effects of
NK cells and anti-PD-L1 antibody with antibody-dependent cellular
cytotoxicity in PD-L1-positive cancer cell lines. J Immunother
Cancer. 8:2020. View Article : Google Scholar
|
|
54
|
Li X, Sun Z, Peng G, Xiao Y, Guo J, Wu B,
Li X, Zhou W, Li J, Li J, Ba C, et al: Single-cell RNA sequencing
reveals a pro-invasive cancer-associated fibroblast subgroup
associated with poor clinical outcomes in patients with gastric
cancer. Theranostics. 12:620–638. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhang W, Edwards A, Flemington EK and
Zhang K: Significant Prognostic Features and Patterns of Somatic
TP53 Mutations in Human Cancers. Cancer Inform.
16:11769351176912672017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ruiz-Cordero R, Ma J, Khanna A, Lyons G,
Rinsurongkawong W, Bassett W, Guo M, Routbort MJ, Zhang J,
Skoulidis F, et al: Simplified molecular classification of lung
adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC
Cancer. 20:832020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Green DR, Ferguson T, Zitvogel L and
Kroemer G: Immunogenic and tolerogenic cell death. Nat Rev Immunol.
9:353–363. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yatim N, Jusforgues-Saklani H, Orozco S,
Schulz O, Barreira da Silva R, Reis e Sousa C, Green DR, Oberst DR
and Albert V: RIPK1 and NF-κB signaling in dying cells determines
cross-priming of CD8+ T cells. Science. 350:328–334. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Pardanani A, Harrison C, Cortes JE,
Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan
E, Vannucchi AM, et al: Safety and efficacy of fedratinib in
patients with primary or secondary myelofibrosis: A randomized
clinical trial. JAMA Oncol. 1:643–651. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chen D, Zhang F, Wang J, He H, Duan S, Zhu
R, Chen C, Yin L and Chen Y: Biodegradable nanoparticles mediated
co-delivery of erlotinib (ELTN) and fedratinib (FDTN) toward the
treatment of ELTN-resistant non-small cell lung cancer (NSCLC) via
suppression of the JAK2/STAT3 signaling pathway. Front Pharmacol.
9:12142018. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Currow D, Temel JS, Abernethy A,
Milanowski J, Friend J and Fearon KC: ROMANA 3: A phase 3 safety
extension study of anamorelin in advanced non-small-cell lung
cancer (NSCLC) patients with cachexia. Ann Oncol. 28:1949–1956.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zinnah KMA, Seol JW and Park SY:
Inhibition of autophagy flux by sertraline attenuates TRAIL
resistance in lung cancer via death receptor 5 upregulation. Int J
Mol Med. 46:795–805. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Liu J, Dong W, Wang T, Liu L, Zhan L, Shi
Y and Han J: Effects of etomidate and propofol on immune function
in patients with lung adenocarcinoma. Am J Transl Res. 8:5748–5755.
2016.PubMed/NCBI
|
|
64
|
Chu CN, Wu KC, Chung WS, Zheng LC, Juan
TK, Hsiao YT, Peng SF, Yang JL, Ma YS, Wu RS and Chung JG:
Etomidate suppresses invasion and migration of human A549 lung
adenocarcinoma cells. Anticancer Res. 39:215–223. 2019. View Article : Google Scholar : PubMed/NCBI
|
